Inovio inventory forecast 2025 refers back to the predicted worth of Inovio Prescribed drugs’ (INO) inventory in 2025. Inventory forecasts are primarily based on numerous elements reminiscent of the corporate’s monetary efficiency, trade developments, and general financial situations.
Inovio is a clinical-stage biotechnology firm centered on growing and commercializing DNA-based immunotherapies for infectious illnesses and most cancers. The corporate’s lead product candidate, INO-4800, is a DNA vaccine for COVID-19 that’s presently in Section 3 medical trials. Inovio additionally has a pipeline of different DNA-based vaccines in growth for numerous infectious illnesses and most cancers indications.
